Dominick Daunno, MD
Internal Medicine · Houston, TXNPI 1881652436
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,604 of the $2,487 with a category attached, or 64.5%. Mylan Specialty L.p. accounts for 73.8% of it on its own, with 12 other manufacturers making up the rest. 2023 is the largest year on record at $1,834, more than ten times the $110 reported in 2020.
Across 46 payments — averaging $54.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$188
- Sunovion Pharmaceuticals Inc.$125
- Lundbeck LLC$101
- Otsuka America Pharmaceutical, Inc.$47
- Corium, LLC$36
- plus $156 from 7 others
Across 144 payments — averaging $77,156 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$9.2M
- Indivior Inc.$801K
- Tris Pharma Inc$765K
- Merck$152K
- Modernatx, Inc.$84K
- AbbVie$70K
- plus $17K from 2 others
What the payments were for
- Travel & lodging$1,60465%
- Food & beverage$88235%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 6 | $1,834 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $188 |
| Sunovion Pharmaceuticals Inc. | 10 | $125 |
| Lundbeck LLC | 5 | $101 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| Corium, LLC | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Indivior Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| MDD US Operations, LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
How this compares
$2,487 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 41 | $12,397 |
| LinzessLinaclotide | 21 | $10,883 |
| EliquisApixaban | 11 | $7,018 |
| MyrbetriqMirabegron | 11 | $5,461 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $2,229 |
| Atorvastatin Calcium | 167 | $2,149 |
| Carbamazepine | 12 | $1,777 |
| Lactulose | 36 | $1,305 |
| Levothyroxine Sodium | 88 | $1,065 |
| Clindamycin Phosphate | 11 | $1,042 |
| Levetiracetam | 12 | $1,006 |
| Ketoconazole | 36 | $902 |
| Alendronate Sodium | 32 | $866 |
| Oxcarbazepine | 12 | $787 |
| Potassium Chloride | 42 | $766 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.